Figure 1From: Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study) Kaplan-Meier plot for progression-free survival in the intention to treat (ITT) population. Back to article page